Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma

Keyphrases

• Anaplastic Large Cell Lymphoma 100%
• Brentuximab Vedotin 100%
• Crizotinib 100%
• Anaplastic Lymphoma Kinase 80%
• Relapsed or Refractory 20%
• First-line Therapy 20%
• CD30 20%
• Response Rate 10%
• Therapeutic Target 10%
• Tyrosine Kinase 10%
• Pediatric Patients 10%
• Remission Rate 10%
• Chemotherapy 10%
• U.S. Food 10%
• Non-small Cell Lung Cancer (NSCLC) 10%
• Complete Response 10%
• Combination Chemotherapy 10%
• Lymphoma Cells 10%
• Antibody-drug Conjugate 10%
• Duration of Response 10%
• Surface Antigen 10%
• Kinase Protein 10%
• Successful Treatment 10%
• Ongoing Trials 10%
• Aggressive Lymphoma 10%
• Antimicrotubule Agents 10%
• T-cell non-Hodgkin Lymphoma 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Brentuximab Vedotin 100%
• Crizotinib 100%
• Anaplastic Large Cell Lymphoma 100%
• Anaplastic Lymphoma Kinase 80%
• Chemotherapy 20%
• Remission 10%
• Protein Tyrosine Kinase 10%
• Non Small Cell Lung Cancer 10%
• Nonhodgkin Lymphoma 10%
• Antibody Drug Conjugate 10%
• Tumor Necrosis Factor Receptor Superfamily Member 8 10%